Loading...
Loading...
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ECYT's earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Endocyte could be a solid choice for investors.
Current Quarter Estimates for ECYT
In the past 30 days, the consensus estimate trend has been pretty favorable, with estimates narrowing from a loss of 14 cents a share 30 days ago, to 11 cents a share today, making a significant move.
Current Year Estimates for ECYT
Meanwhile, Endocyte's current year figures are also looking quite promising, with the consensus estimate trend narrowing from a loss of 43 cents per share 30 days ago to a loss of 34 cents per share today, an increase of 20.9%.
Bottom Line
The stock has also started to move higher lately, adding 5.2% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free reportENDOCYTE INC ECYT: Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: Long IdeasTrading Ideas
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in